Coastal Infusion Administers Onpattro^®

Onpattro (patisiran) is a medicine used to treat nerve damage caused by hereditary transthyretin (hATTR) amyloidosis, a disease in which abnormal proteins called amyloids build up in tissues around the body including around the nerves. Onpattro is used in adult patients in the first two stages of nerve damage.

In patients with hATTR amyloidosis, a protein called transthyretin which circulates in the blood is defective and breaks easily. The broken protein forms amyloid deposits in tissues and organs around the body, including around nerves, where it interferes with their normal functions.

The active substance in Onpattro, patisiran, is a small interfering RNA (siRNA), a short piece of synthetic genetic material that has been designed to attach to and block the genetic material of the cell responsible for producing transthyretin. This reduces production of defective transthyretin, thereby reducing the formation of amyloids and relieving the symptoms of hATTR amyloidosis.

What It Treats

Onpattro is used to treat polyneuropathy caused by hereditary ATTR (hATTR) amyloidosis.

Prescribed By

Onpattro is most often prescribed by Neurologists, Geneticists, and Cardiologists.

How it's Administered

Onpattro is administered by intravenous infusion. Onpattro infusions take about 90 minutes.

Frequency

Onpattro is generally administered every three weeks.

Related Drugs

Amvuttra

Additional Resources

The information on this page is compiled from a variety of online sources. Coastal Infusion has made every effort to verify its accuracy, but patients are advised to discuss any planned or current treatments with their doctor. Report inaccuracies